Citius Pharmaceuticals Management
Management criteria checks 2/4
Citius Pharmaceuticals' CEO is Leonard Mazur, appointed in Mar 2016, has a tenure of 8.67 years. total yearly compensation is $1.98M, comprised of 24% salary and 76% bonuses, including company stock and options. directly owns 5.31% of the company’s shares, worth $1.37M. The average tenure of the management team and the board of directors is 3.8 years and 8.5 years respectively.
Key information
Leonard Mazur
Chief executive officer
US$2.0m
Total compensation
| CEO salary percentage | 24.0% |
| CEO tenure | 8.7yrs |
| CEO ownership | 5.3% |
| Management average tenure | 3.8yrs |
| Board average tenure | 8.5yrs |
Recent management updates
Recent updates
We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully
Apr 06
We're Keeping An Eye On Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Rate
Dec 08Will Citius Pharmaceuticals (NASDAQ:CTXR) Spend Its Cash Wisely?
Aug 01We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth
Apr 12Here's Why We're Watching Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation
Dec 25Citius Pharma submits biologics license application to FDA for immunotherapy I/ONTAK
Sep 28Citius Pharmaceuticals GAAP EPS of -$0.06
Aug 11Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely
Aug 05Citius holds pre-biologics license application meeting with FDA for immunotherapy I/ONTAK
Jul 12Citius Pharmaceuticals: Hoping For A Turnaround Strategy
Jul 05Critical Care Biopharma - Citius Pharmaceuticals
Apr 13Citius: 2022 Is A Year Of Catalysts
Mar 28We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth
Dec 04Citius Pharmaceuticals, Inc.: Burning Cash Before Commercialization
Sep 26Companies Like Citius Pharmaceuticals (NASDAQ:CTXR) Are In A Position To Invest In Growth
Aug 28Citius: Halt For Superiority On The Horizon
Jun 15We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth
May 15Citius Pharmaceuticals shares rise in anticipation of Mino-Lok phase 3 results
Apr 26Is Citius Pharmaceuticals (NASDAQ:CTXR) In A Good Position To Deliver On Growth Plans?
Dec 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$40m |
| Mar 31 2024 | n/a | n/a | -US$37m |
| Dec 31 2023 | n/a | n/a | -US$39m |
| Sep 30 2023 | US$2m | US$475k | -US$34m |
| Jun 30 2023 | n/a | n/a | -US$31m |
| Mar 31 2023 | n/a | n/a | -US$31m |
| Dec 31 2022 | n/a | n/a | -US$28m |
| Sep 30 2022 | US$1m | US$400k | -US$34m |
| Jun 30 2022 | n/a | n/a | -US$31m |
| Mar 31 2022 | n/a | n/a | -US$29m |
| Dec 31 2021 | n/a | n/a | -US$26m |
| Sep 30 2021 | US$788k | US$348k | -US$25m |
| Jun 30 2021 | n/a | n/a | -US$24m |
| Mar 31 2021 | n/a | n/a | -US$21m |
| Dec 31 2020 | n/a | n/a | -US$21m |
| Sep 30 2020 | US$550k | US$250k | -US$18m |
| Jun 30 2020 | n/a | n/a | -US$17m |
| Mar 31 2020 | n/a | n/a | -US$17m |
| Dec 31 2019 | n/a | n/a | -US$16m |
| Sep 30 2019 | US$473k | US$250k | -US$16m |
| Jun 30 2019 | n/a | n/a | -US$15m |
| Mar 31 2019 | n/a | n/a | -US$12m |
| Dec 31 2018 | n/a | n/a | -US$13m |
| Sep 30 2018 | US$398k | US$250k | -US$13m |
Compensation vs Market: Leonard's total compensation ($USD1.98M) is above average for companies of similar size in the US market ($USD650.80K).
Compensation vs Earnings: Leonard's compensation has increased whilst the company is unprofitable.
CEO
Leonard Mazur (79 yo)
8.7yrs
Tenure
US$1,981,113
Compensation
Mr. Leonard L. Mazur is Chairman, Chief Executive Officer & President of Citius Oncology, Inc. from August 12, 2024. Mr. Mazur has been Chief Executive Officer of Citius Pharmaceuticals, Inc. since May 01,...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 8.7yrs | US$1.98m | 5.31% $ 1.4m | |
| Co-Founder & Executive Vice Chairman | 9.1yrs | US$1.59m | 1.03% $ 266.6k | |
| Executive VP & Chief Medical Officer | 4.3yrs | US$1.17m | 0% $ 0 | |
| Chief Business Officer | 7yrs | US$809.00k | 0.031% $ 8.1k | |
| Executive Vice President of Operations | 8.7yrs | no data | no data | |
| Vice President of Investor Relations & Corporate Communications | no data | no data | no data | |
| Senior VP and Head of Clinical Operations & Quality Assurance | 2.8yrs | no data | no data | |
| Senior Vice President of Business Strategy | 3.8yrs | no data | no data | |
| Executive Vice President of Chemistry | 3yrs | no data | no data | |
| Executive Vice President of Quality Assurance | 1.8yrs | no data | no data | |
| Executive Vice President of Regulatory Affairs | 1.2yrs | no data | no data |
3.8yrs
Average Tenure
69.5yo
Average Age
Experienced Management: CTXR's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 10.2yrs | US$1.98m | 5.31% $ 1.4m | |
| Co-Founder & Executive Vice Chairman | 9.1yrs | US$1.59m | 1.03% $ 266.6k | |
| Independent Director | 1.8yrs | US$150.13k | 0% $ 0 | |
| ARDS Scientific Advisory Board Member | no data | no data | no data | |
| Independent Director | 9.1yrs | US$196.97k | 0% $ 0 | |
| Independent Director | 8.7yrs | US$190.97k | 0.0061% $ 1.6k | |
| Independent Director | 8.4yrs | US$190.97k | 0.0012% $ 317.9 | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 6.3yrs | no data | no data | |
| ARDS Scientific Advisory Board Member | 3.4yrs | no data | no data | |
| ARDS Scientific Advisory Board Member | no data | no data | no data |
8.5yrs
Average Tenure
77yo
Average Age
Experienced Board: CTXR's board of directors are considered experienced (8.5 years average tenure).